Lantern Pharma (LTRN) Competitors $3.14 -0.07 (-2.18%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LTRN vs. ADAP, PBYI, ELUT, TIL, BDTX, GALT, MNPR, CGEN, JATT, and TELOShould you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Adaptimmune Therapeutics (ADAP), Puma Biotechnology (PBYI), Elutia (ELUT), Instil Bio (TIL), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Monopar Therapeutics (MNPR), Compugen (CGEN), JATT Acquisition (JATT), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry. Lantern Pharma vs. Adaptimmune Therapeutics Puma Biotechnology Elutia Instil Bio Black Diamond Therapeutics Galectin Therapeutics Monopar Therapeutics Compugen JATT Acquisition Telomir Pharmaceuticals Lantern Pharma (NASDAQ:LTRN) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk. Which has more risk and volatility, LTRN or ADAP? Lantern Pharma has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Which has stronger valuation & earnings, LTRN or ADAP? Lantern Pharma has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantern PharmaN/AN/A-$15.96M-$1.78-1.76Adaptimmune Therapeutics$175.04M0.88-$113.87M-$0.22-2.75 Does the media favor LTRN or ADAP? In the previous week, Adaptimmune Therapeutics had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Adaptimmune Therapeutics and 0 mentions for Lantern Pharma. Adaptimmune Therapeutics' average media sentiment score of 0.04 beat Lantern Pharma's score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lantern Pharma Neutral Adaptimmune Therapeutics Neutral Does the MarketBeat Community believe in LTRN or ADAP? Adaptimmune Therapeutics received 305 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 63.02% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformLantern PharmaOutperform Votes1275.00% Underperform Votes425.00% Adaptimmune TherapeuticsOutperform Votes31763.02% Underperform Votes18636.98% Do insiders and institutionals have more ownership in LTRN or ADAP? 28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 7.3% of Lantern Pharma shares are held by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is LTRN or ADAP more profitable? Lantern Pharma has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -25.43%. Lantern Pharma's return on equity of -56.91% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lantern PharmaN/A -56.91% -51.17% Adaptimmune Therapeutics -25.43%-74.15%-15.09% Do analysts prefer LTRN or ADAP? Adaptimmune Therapeutics has a consensus target price of $2.79, indicating a potential upside of 360.82%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAdaptimmune Therapeutics beats Lantern Pharma on 12 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTRN vs. The Competition Export to ExcelMetricLantern PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.92M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-1.7610.5991.3417.19Price / SalesN/A195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book0.845.104.794.78Net Income-$15.96M$151.51M$120.07M$225.60M7 Day Performance-8.85%-2.15%-1.90%-1.23%1 Month Performance6.44%-3.14%11.45%3.37%1 Year Performance-23.97%11.50%30.63%16.58% Lantern Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTRNLantern PharmaN/A$3.14-2.2%N/A-19.1%$33.92MN/A-1.7620ADAPAdaptimmune Therapeutics1.9073 of 5 stars$0.59+1.8%$2.79+372.1%+37.1%$151.10M$60.28M-2.64449News CoveragePBYIPuma Biotechnology3.9481 of 5 stars$3.02+4.9%$7.00+131.8%-30.0%$148.25M$243.57M6.42185Positive NewsELUTElutia2.7375 of 5 stars$4.20+1.4%$10.00+138.1%+148.2%$145.15M$24.75M-1.59180TILInstil Bio2.8565 of 5 stars$22.13+0.7%$145.00+555.2%+196.5%$144.42MN/A-1.9149BDTXBlack Diamond Therapeutics2.361 of 5 stars$2.54-0.8%$15.50+510.2%-16.2%$143.73MN/A-1.9290Positive NewsGap DownGALTGalectin Therapeutics1.9706 of 5 stars$2.28+8.1%$11.00+382.5%-39.2%$143.10MN/A-3.149News CoverageGap DownHigh Trading VolumeMNPRMonopar Therapeutics1.975 of 5 stars$27.06+6.6%$27.33+1.0%+1,165.4%$142.82MN/A-12.8810News CoverageGap UpCGENCompugen1.5938 of 5 stars$1.59-1.6%$4.00+152.4%-17.3%$141.44M$59.85M80.5068JATTJATT AcquisitionN/A$8.16-24.1%N/A-51.6%$140.76MN/A0.003High Trading VolumeTELOTelomir PharmaceuticalsN/A$4.75-8.7%N/AN/A$140.65MN/A0.001High Trading Volume Related Companies and Tools Related Companies ADAP Alternatives PBYI Alternatives ELUT Alternatives TIL Alternatives BDTX Alternatives GALT Alternatives MNPR Alternatives CGEN Alternatives JATT Alternatives TELO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LTRN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
